Table 1.
Patient characteristics and, from gamma counts, urinary excretion and blood SUV
| Pt # | Study | A/S/R/M | Tumor | Clinical status | % Ex (urine) | SUVa (Bld) |
|---|---|---|---|---|---|---|
| 1 | BD & IHC | 63/M/CC/73.6 | GBM | ND | 13.5 | 0.61 |
| 2 | BD & IHC | 63/M/CC/95.9 | EsoMet | PT/Rec | 13.4 | 0.91 |
| 3 | BD & IHC | 65/M/CC/96.4 | GBM | ND | 15.8 | 0.69 |
| 4 | BD | 61/M/CC/87.0 | NSCLC | PT/RS | 5.1 | 0.80b |
| 5 | BD | 44/F/CC/70.5 | NSCLC | ND | 20.4 | 0.54 |
| 6 | BD | 48/F/CC/74.5 | mmM/E/U | ND | 16.2 | 0.62 |
| 7 | BD | 64/M/AA/81.8 | NSCLC | ND | 11.3 | 0.73 |
| 8 | BD | 59/F/AA/80.4 | ODG | OT | 14.4 | 0.74 |
| 9 | BD | 58/M/CC/78.2 | UP | PT | 11.3 | 0.49 |
| 10 | BD | 62/F/CC/53.2 | NSCLC | PT | 12.9 | 1.23 |
A/S/R/M age/sex/race (CC Caucasian, AA African American)/Patient Mass (Kg), % Ex % excretion, Bld blood, BD biodistribution, IHC immunohistochemistry, GBM glioblastoma multiforme, EsoMet esophageal metastasis, NSCLC non-small cell lung cancer, mM/E/U malignant mixed Mullerian cancer (endometrium/uterus), ODG oligodendroglioma, UP unknown primary, ND newly diagnosed, PT/Rec prior therapy/recurrence, PT/RS prior therapy, restaged, PT/OT prior therapy/off treatment
a
Average of three samples (1 per scan)
b
This SUV should be closer to 0.6 since first time point taken at only 2 min post-injection